Agilent Technologies Inc. (NYSE: A) has expanded its portfolio of target-enrichment products with the introduction of HaloPlex exome kits and SureCall software.
“These products simplify the sequencing of clinical research samples,” said Olle Ericsson, Agilent director of marketing for DNA sequencing. “The HaloPlex Exome delivers streamlined capture of all coding exons, with low input sample requirements, on all Illumina sequencing platforms. Together with SureDesign, and the SureCall software, these products constitute a very comprehensive clinical research solution for target enrichment.”
The HaloPlex exome kit comprises about 2.5 million probes to provide efficient and comprehensive coverage of the coding regions of the human genome with minimal hands-on time and requires only 200 ng of input DNA.
“The HaloPlex exome provides an easy workflow for all-exon analysis enabling short turnaround sequencing with low DNA input amounts,” said Dr. Wilfred van IJcken, assistant professor at Erasmus MC and an early access user who also will present at the 14th annual Advances in Genome Biology and Technology meeting, Feb. 20-23, in Marco Island, Fla.
SureDesign, which has logged over 15,000 designs since it was launched in October, enables clinical researchers to create a custom panel tailored to their needs. With this interface, researchers can quickly generate exceptionally flexible designs for high-performance, targeted resequencing, using Agilent's HaloPlex and SureSelect systems. In just three simple steps, researchers can create custom sequencing panels tailored to their specific projects. To provide confidence in the analysis, any custom gene-sequencing panel can be created based on the 2.5 million probes from the HaloPlex exome kit.
SureCall data analysis software is designed to maximize clinical laboratory throughput by dramatically simplifying the analysis workflow for next-generation sequencing data. The software is fast, reliable and easy to use, with a three-step workflow process that translates raw data into a report with genetic variants classified and ranked in a matter of hours. Its end-to-end capabilities make it more cost effective than other methods and enable clinical researchers to focus on their results rather than cumbersome analysis processes by eliminating the expensive, time-consuming data analysis bottleneck.